YARDLEY, Pa., July 1, 2011 /PRNewswire/ -- PetArmor™ and PetArmor™ Plus currently remain available for sale at retail outlets, despite competitor statements to the contrary.
Last week, the United States District Court for the Middle District of Georgia granted motions filed by Merial Limited and Merial SAS for contempt against Velcera and FidoPharm and their contract manufacturer for PetArmor Plus, Cipla Limited. However, the court has stayed its order for 60 days to allow time for an appeal to the United States Court of Appeals for the Federal Circuit, where the stay could be further extended.
Velcera and FidoPharm intend to seek an expedited appeal and will vigorously defend their ability to continue selling PetArmor Plus, the first generic fipronil and S-methoprene product available on retail shelves in the United States.
Additionally, the validity of Merial's patent was not addressed in the Georgia court proceedings. Velcera and FidoPharm continue to maintain that they do not infringe any valid claim of the Merial patent in question, and they are currently pursuing claims of non-infringement and invalidity in federal district court in Delaware.
"We want to assure pet owners that we remain passionate about providing their pets the protection they need at prices they can afford," said FidoPharm President Alex Kaufman.
FidoPharm is a leading pet health products company committed to providing consumers with best-in-class pet health products that contain the same active ingredients as branded products but at a significantly lower cost. FidoPharm products are available at major retailers nationwide, offering consumers the benefits of convenience and cost savings to ensure the highest quality care for their pets. Learn more at www.PetArmor.com.